The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated.
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas / E. Berrino, L. Annaratone, S.E. Bellomo, G. Ferrero, A. Gagliardi, A. Bragoni, D. Grassini, S. Guarrera, C. Parlato, L. Casorzo, M. Panero, I. Sarotto, S. Giordano, M. Cereda, F. Montemurro, R. Ponzone, N. Crosetto, A. Naccarati, A. Sapino, C. Marchiò. - In: GENOME MEDICINE. - ISSN 1756-994X. - 14:1(2022), pp. 98.1-98.16. [10.1186/s13073-022-01104-z]
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
M. Cereda;
2022
Abstract
The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s13073-022-01104-z.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
7.96 MB
Formato
Adobe PDF
|
7.96 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
